Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Volume 18, Issue 3, Pages (March 2010)
Advertisements

Guido Tomás Rozenblum, Tomás Kaufman, Alfredo Daniel Vitullo 
Volume 12, Issue 5, Pages (November 2005)
Volume 15, Issue 6, Pages (June 2007)
Molecular Therapy - Oncolytics
Volume 16, Issue 3, Pages (March 2008)
Volume 25, Issue 10, Pages (October 2017)
Molecular Therapy - Nucleic Acids
Single Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy  Yuka Igarashi, Toru Uchiyama, Tomoko Minegishi, Sirirat.
Molecular Therapy - Oncolytics
Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?
Volume 17, Issue 11, Pages (November 2009)
Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes by Julie Dyall, Jean-Baptiste.
Volume 20, Issue 7, Pages (July 2012)
Specific Lysis of Melanoma Cells by Receptor Grafted T Cells is Enhanced by Anti- Idiotypic Monoclonal Antibodies Directed to the scFv Domain of the Receptor 
Volume 134, Issue 1, Pages (January 2008)
Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo by Suzanne M. McGoldrick, Marie E. Bleakley,
Volume 10, Issue 5, Pages (November 2004)
Volume 15, Issue 1, Pages (January 2007)
Volume 12, Issue 6, Pages (December 2005)
Volume 22, Issue 3, Pages (March 2014)
Neeltje A Kootstra, Ryusuke Matsumura, Inder M Verma  Molecular Therapy 
Volume 20, Issue 5, Pages (May 2012)
Volume 26, Issue 2, Pages (February 2018)
Volume 10, Issue 1, Pages (July 2004)
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)‏ by Michaela Scherr, Anuhar Chaturvedi, Karin.
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Molecular Therapy - Methods & Clinical Development
Volume 1, Issue 5, Pages (May 2000)
Volume 20, Issue 5, Pages (May 2012)
The Other Face of Chimeric Antigen Receptors
Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor  Alexander Falkenhagen, Jastaranpreet Singh, Sabah Asad, Danila Leontyev,
Volume 23, Issue 4, Pages (April 2015)
Molecular Therapy - Oncolytics
Volume 17, Issue 2, Pages (February 2009)
Volume 24, Issue 9, Pages (September 2016)
Volume 20, Issue 10, Pages (October 2012)
Volume 15, Issue 9, Pages (September 2007)
Molecular Therapy - Methods & Clinical Development
Volume 12, Issue 5, Pages (November 2005)
Volume 23, Issue 1, Pages (January 2015)
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
Volume 19, Issue 2, Pages (February 2011)
Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8+ T-cell Activation Against Tumors  Benjamin J Umlauf, Chin-Ying.
Volume 19, Issue 4, Pages (April 2011)
Volume 15, Issue 8, Pages (August 2007)
Molecular Therapy - Nucleic Acids
Volume 21, Issue 8, Pages (August 2013)
Morvarid Moayeri, Teresa S. Hawley, Robert G. Hawley  Molecular Therapy 
Volume 11, Issue 6, Pages (June 2005)
Molecular Therapy - Nucleic Acids
Volume 26, Issue 2, Pages (February 2018)
Molecular Therapy - Methods & Clinical Development
Volume 24, Issue 2, Pages (February 2016)
Volume 15, Issue 9, Pages (September 2007)
Volume 20, Issue 3, Pages (March 2012)
Molecular Therapy - Nucleic Acids
Volume 2, Issue 4, Pages (October 2000)
Volume 23, Issue 4, Pages (April 2015)
Molecular Therapy - Oncolytics
Antigen Selection of Anti-DSG1 Autoantibodies During and Before the Onset of Endemic Pemphigus Foliaceus  Ye Qian, Stephen H. Clarke, Valeria Aoki, Gunter.
Volume 21, Issue 4, Pages (April 2013)
Charles A Wuertzer, Mark A Sullivan, Xing Qiu, Howard J Federoff 
Molecular Therapy - Methods & Clinical Development
Volume 17, Issue 11, Pages (November 2009)
CD28 Aptamers as Powerful Immune Response Modulators
Analysis of Type 2 Immunity In Vivo with a Bicistronic IL-4 Reporter
Molecular Therapy - Methods & Clinical Development
Volume 20, Issue 9, Pages (September 2012)
Molecular Therapy - Nucleic Acids
Presentation transcript:

Molecular Therapy - Nucleic Acids CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors  Vanesa Alonso-Camino, David Sánchez-Martín, Marta Compte, Natalia Nuñez-Prado, Rosa M Diaz, Richard Vile, Luis Alvarez-Vallina  Molecular Therapy - Nucleic Acids  Volume 2, (January 2013) DOI: 10.1038/mtna.2013.19 Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Schematic representation of the lentiviral vector encoding a first generation chimeric antigen receptor (CAR). (a) Bicistronic vector (pRRL.Griffin.CAR) containing a human scFv repertoire in a first-generation TCRζ-based CAR and the EGFP gene. (b) FACS analysis of EGFP and cell surface CAR expression after transduction of Jurkat cells with either anti-CEA.CAR or Griffin.CAR encoding lentiviral vectors (LVαCEA.CAR and LVGriffin.CAR, respectively) at multiplicity of infectionI of ~1. Δ gag, ATG-deleted group specific antigen; CMV promoter, cytomegalovirus promoter; EGFP, enhanced green fluorescent protein; EMCV IRES, encephalomyocarditis virus internal ribosomal entry site; FACS, fluorescence-activated cell sorting; LTR, long terminal repeats; LV, lentiviral vector; RRE, Rev-responsive cis-acting element; scFv, single-chain variable fragment; TCR, T cell receptor. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.19) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Selection of chimeric antigen receptor (CAR)-activated Jurkat T cells. JurkatGriffin.CAR cells were stimulated with HeLa cells for 16 hours and further sorted on the basis of enhanced green fluorescent protein (EGFP) and CD69 expression. After a period of cell expansion, the activation/selection cycle was repeated two additional times. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.19) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Evolution of library diversity in the successive rounds of selection. (a) Sequence analysis confirmed that in the naive library there were not repeated sequences, except the B1.8 scFv gene that represents a 30% of the clones. Whereas the number of non-B1.8 repeated clones increased after each successive round of selection, the percentage of B1.8 clones remained constant along the selection process. (b) Enrichment observed in the different rounds of selection in the VL (upper) or the VH (lower). The lowest 100 P values in each of 500 simulations (psim) are sorted in ascending order (x-axis) and plotted in light gray. The observed lowest 100 P values (pobs) are overlaid in red for a better comparison (round 3, pobs are tangential to the x-axis). (c) The observed 500 lowest P values (pobs) of all the possible triplets of amino acids in the CDRs are plotted to compare the progressive enrichment in the different rounds (blue = S1, red = S2, green = S3) in the VL (upper) or the VH (lower). CDR, complementarity determining region; scFv, single-chain variable fragment. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.19) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Evaluation of selected binders. (a) The presence of myc/6xHis-tagged soluble CARbodies in cell-free bacterial supernatant was demonstrated by western blot analysis, and ELISA against HeLa air-dried and fixed cells, using anti-c-myc mAb and HRP-conjugated goat anti-mouse IgG antibody. (b) The antigenic integrity was assessed with anti-MHC class I (W6/32) and anti-cytokeratin (A1/A3) mAbs. (c) The reactivity of a representative panel of soluble scFvs selected after one, two, and three rounds of selection was determined by ELISA. Myc/6xHis-tagged anti-NIP (B1.8) and anti-CEA (MFE23) scFvs were used as negative control to establish the background signal of the system (as shown in c). HRP, horseradish peroxidise; mAb, monoclonal antibody; MHC, major histocompatibility complex; scFv, single-chain variable fragment. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.19) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Phenotypic and functional characterization of JurkatS3.45.CARv2, JurkatS3.97.CARv2, and JurkatS3.109.CARv2. (a) Comparative analysis of EGFP and cell surface expression of the selected CARbodies S3.45, S3.97, and S3.109 in the context of a second-generation CAR after transduction of Jurkat cells with LVS3.45.CARv2, LVS3.97.CARv2, and LVS3.109.CARv2 lentiviral vectors at multiplicity of infection of ~30. (b) FACS analysis of CD69 and EGFP expression by JurkatS3.45.CARv2, JurkatS3.97.CARv2, and JurkatS3.109.CARv2 stimulated either with HeLa (E:T = 1:1) for 16 hours. CAR, chimeric antigen receptor; EGFP, enhanced green fluorescent protein; E:T ratio, effector:target ratio; FACS, fluorescence-activated cell sorting; LV, lentiviral vector. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.19) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Phenotypic and functional characterization of human peripheral blood lymphocytes transduced with CARbodies-based CAR. (a) Comparative analysis of EGFP and cell surface expression of the selected CARbodies after transduction of human lymphocytes with LVαCEA.CARv2, LVS3.45.CARv2, and LVS3.109.CARv2 lentiviral vectors at multiplicity of infection of ~20. (b) IFN-γ secretion by untransduced PBL, or transduced PBL (PBLαCEA.CARv2 and PBLS3.45.CARv2) following incubation with HeLa or HeLaCEA cells. CAR, chimeric antigen receptor; EGFP, enhanced green fluorescent protein; IFN, interferon; LV, lentiviral vector; PBL, peripheral blood lymphocyte. Molecular Therapy - Nucleic Acids 2013 2, DOI: (10.1038/mtna.2013.19) Copyright © 2013 American Society of Gene & Cell Therapy Terms and Conditions